LNX231

LNX231 is an orally bioavailable multi-kinase inhibitor primarily targeting FMS-like tyrosine kinase 3 (FLT3), including its mutant forms FLT3-ITD and FLT3-D835Y. Developed by Lunan Pharmaceutical Group and Shandong New Time Pharmaceutical, it is currently a preclinical candidate for the treatment of FLT3-mutated acute myeloid leukemia (AML). LNX231 exerts its anti-tumor effects by inhibiting the RAS-MAPK and JAK-STAT signaling pathways, which leads to reduced phosphorylation of STAT5 and ERK. Preclinical data demonstrate that LNX231 induces sustained tumor shrinkage in AML models, showing greater potency than gilteritinib, and may also enhance tumor immunity. It features a favorable ADMET profile and low cardiotoxicity.